– 16 April 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
– 13 February 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and…
– 03 December 2024
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
– 18 November 2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in…
– 15 November 2024
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with…
– 23 October 2024
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its…
– 23 September 2024
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare…
– 20 September 2024
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary…
– 10 June 2024
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary…
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 213 Press Releases
–
24 April 2025
24 April 2025
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
PARIS, FRANCE, 24 April 2025 Ipsen (Euronext: IPN; ADR: IPSEY) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver (EASL) congress as…
–
16 April 2025
16 April 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full-year 2025 financial guidance. PARIS,…
–
08 April 2025
08 April 2025
Ipsen publishes its 2024 Universal Registration Document
Ipsen publishes its 2024 Universal Registration Document
–
19 March 2025
19 March 2025
Ipsen announces issuance of €500 million inaugural Rated Public Bond
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s
–
12 March 2025
12 March 2025
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
PARIS, FRANCE, March 12th, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025. She will serve on Ipsen’s Executive Leadership…
Your dedicated contacts
-
Media Relations
-
Stay updated